TB-500 Dosage Chart
Loading and maintenance protocols, weekly schedule, and reconstitution math for the 5 mg vial — plus how TB-500 fits the Wolverine Stack.
Educational tool — not medical advice. This calculator provides estimates based on population averages and published trial data. Outputs are not clinical recommendations and do not replace evaluation by a qualified prescriber. Do not start, stop, or change a peptide therapy based on the result of this tool.
TB-500 is a synthetic peptide marketed as functionally equivalent to a fragment of Thymosin Beta-4. Full-length Thymosin Beta-4 has Phase 2 trial data (RegeneRx, primarily in dry eye and epidermolysis bullosa) but TB-500 itself has no human dose-ranging trials. The protocols below reflect commonly cited practitioner schedules in athletic recovery and 503A/503B compounding settings.
TB-500 at a Glance
| Typical loading dose | 2–2.5 mg subQ, 2× per week (Mon/Thu pattern is common) |
|---|---|
| Typical maintenance dose | 2 mg subQ, 1× per week |
| Route | Subcutaneous injection (abdomen or thigh) — systemic, not localized |
| Cycle length | 4–6 week loading, then 4–6 week maintenance, then 4-week break |
| FDA status | Not FDA-approved. Compounded; banned by WADA for athletes. |
| Source quality | Full-length TB4 has limited clinical trial data; TB-500 dosing is practitioner-derived. |
| Common vial size | 2 mg, 5 mg, or 10 mg lyophilized powder |
TB-500 Reconstitution Chart
How vial size, bacteriostatic water volume, and insulin-syringe units convert for TB-500. Use this to translate a prescribed mcg or mg dose into a syringe measurement.
| Vial size | Bac water | Concentration | Dose → insulin-syringe units (U-100) |
|---|---|---|---|
| 5 mg | 2 mL | 2.5 mg/mL (250 mcg per 0.1 mL) |
|
| 5 mg | 2.5 mL | 2 mg/mL (200 mcg per 0.1 mL) |
|
| 10 mg | 5 mL | 2 mg/mL (200 mcg per 0.1 mL) |
|
U-100 syringe reference: 100 units = 1.0 mL. So 10 units = 0.1 mL, 25 units = 0.25 mL, 50 units = 0.5 mL. TB-500 doses are larger than BPC-157 — most full doses span the entire usable range of a U-100 insulin syringe. Many practitioners split the dose into two injection sites.
TB-500 Dosing by Use Case
Commonly cited protocols vary by what TB-500 is being used for. The table below summarizes typical ranges reported in clinical practice and published literature.
| Use case | Typical dose | Frequency | Cycle length | Notes |
|---|---|---|---|---|
| Acute injury (loading phase) | 2–2.5 mg | 2× per week | 4–6 weeks | Systemic subQ. Most-cited protocol pattern is Monday + Thursday. |
| Chronic injury / maintenance | 2 mg | 1× per week | 4–6 weeks following loading | Following the loading phase, drop to weekly dosing as a maintenance taper. |
| Performance recovery (off-season) | 2 mg | Every 2 weeks | 8–12 weeks total | Lower-frequency protocol used by athletes in off-season recovery work. |
Stacking TB-500
TB-500 is most commonly stacked with BPC-157 — the combination is known as the Wolverine Stack and targets soft-tissue and tendon recovery. The two are typically injected at different sites (TB-500 systemic, BPC-157 near injury) and not mixed in the same syringe.
TB-500 is reported to be well-tolerated at typical doses, but its angiogenic and pro-migratory activity raises specific concerns in patients with malignancy.
- •Theoretical concern: TB-500 promotes angiogenesis and cell migration — both pathways implicated in tumor growth and metastasis. Most clinicians contraindicate TB-500 in patients with active or recent cancer.
- •Reported side effects: lethargy, mild head rush after injection, injection-site reactions.
- •Banned by the World Anti-Doping Agency (WADA) for competitive athletes.
- •Not FDA-approved for human use; access is via 503A/503B compounding pharmacies under provider prescription.
- •Do not co-mix with BPC-157 in the same syringe without explicit pharmacy guidance.
- •You have an active or recent cancer diagnosis or strong family history of cancer
- •You are pregnant, breastfeeding, or trying to conceive
- •You compete in a sport governed by WADA or any sanctioning body that follows the WADA Prohibited List
TB-500 Dosing FAQ
TB-500 has a longer functional duration than BPC-157, which is why most protocols dose it 1–2× weekly rather than daily. Practitioner schedules typically assume effective tissue activity for several days after each injection.
Most practitioners inject TB-500 systemically (abdomen or thigh) rather than at the injury site. The molecule is larger, has a longer half-life, and is believed to distribute systemically — localized injection isn't typically considered necessary.
A common pattern is weeks 1–4 at 2–2.5 mg twice weekly (loading), then weeks 5–8 at 2 mg once weekly (maintenance). Practitioners then take a 4-week break before any repeat cycle.
Not exactly. TB-500 is a synthetic peptide marketed as functionally equivalent to an active fragment of Thymosin Beta-4. Full-length TB4 has been studied in formal clinical trials by RegeneRx; the TB-500 fragment available through compounding is not the identical molecule, though the mechanisms cited are similar.
Sources
Related Dosage Charts
Want the full TB-500 guide?
Mechanism, clinical evidence, side effects, costs, and provider listings for TB-500 therapy.
See TB-500 guideMedical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.